Key Takeaways
- Resilient quarter, margin miss: Revenue mix continued shifting toward pharma (61% of sales), but EBITDA missed the company's own expectation by INR2–3 crores as fuel costs stayed elevated and paracetamol pricing weakened.
- FY27 growth bet is explicit: Management guided to 10–15% top-line and 15–20% bottom-line growth next year, anchored on paracetamol ramp-up, non-ibuprofen API traction, and regulated-market exports.
- The margin story has been repeatedly reset: The EBITDA target has drifted from 14–15% to 13% to a current understanding of ~11–12%, with a 1–2% improvement promised for Q4.
- Non-ibuprofen shift is the structural thesis: Ibuprofen share within APIs fell 2% YoY; the near-term target is a 50:50 ibuprofen/non-ibuprofen split, with an ideal end-state of 25:75.
- What to watch next quarter: Whether the promised Q4 EBITDA margin uptick materializes, any quantification of paracetamol pricing recovery, and progress on minoxidil API commercialization in regulated markets.
Performance & Segment Dynamics
- Pharma anchored growth: The segment continued to drive the top line, with non-ibuprofen molecules like metformin, pantoprazole, and clopidogrel gaining share. This shift reduces concentration risk and strengthens margin quality, per management.
- Ibuprofen running full, competitive pressure contained: Capacity utilization exceeded 90%, a competitor's US plant closed last year, and global demand grows 3–4% annually. Management indicated IOL is not facing the same competitive intensity as peers.
- Chemicals stable, EBIT nearly doubled in 9M: Full utilization of the ethyl acetate plant drove the improvement. The segment's EBIT margin improved sequentially from 1.8% to 2.2% on better throughput.
- Pharma EBIT margin slipped sequentially: Declined from 10.5% to ~9.7% as paracetamol prices fell and that plant ran at only ~60% utilization. Management's volume-over-price strategy compressed margins.
- Power and fuel costs stayed sticky: Rice husk prices did not retreat as expected after Q2's Punjab floods, so the cost burden carried into Q3. Marketing and general expenses also inched up.
- One-time labor-law charge: An exceptional loss of INR11.21 crores was booked for gratuity and earned-leave provisions under the new consolidated labor codes, a non-recurring item.
Khanna: "In respect to EBITDA margin, we are not able to achieve the target because of unexpected rise in the fuel cost. So now we hope we will do better in the coming quarter."
Revenue Mix & Strategic Targets
- Pharma share rose 4pp YoY to 61%: Within APIs, ibuprofen share declined 2% and non-ibuprofen increased 2%, consistent with the deliberate diversification strategy.
- Near-term mix target (2 years): 60% API, 40% chemical. The ideal long-term split is 75% API, 25% chemical.
- API sub-targets: Move to 50:50 ibuprofen/non-ibuprofen in the near term, then further to 25:75. The FY27 revenue plan of INR2,700 crores assumes INR1,800 crores from API and INR900 crores from chemicals at that 50:50 ratio.
Singh: "The ideal we are thinking is 25% and 75%. So 25% from the chemical and 75% from the API. And between these APIs, the near-term objective of ours is to divide it into the 50-50."
Margin Trajectory & Cost Realities
- EBITDA target repeatedly revised down: From an initial 14–15% aspiration, to 13%, to a current understanding of roughly 11–12%. Management now frames FY27 as the year margins get better.
- Q4 margin promise: The company expects to improve EBITDA margin by 1–2% in Q4 and is "very sure" the INR2–3 crores Q3 miss will be recovered. Q4 revenue is pegged at approximately INR600 crores with EBITDA margin a little above 11%.
- Pricing is the acknowledged blind spot: Management declined to give a specific EBITDA margin number, stating it cannot control prices and prefers to answer questions on quantity and capacity utilization.
- Volume strategy compressed pharma margins: Running plants for utilization rather than price optimization hurt, particularly in paracetamol. The company says future focus will include pricing, not just volume.
Singh: "Initially we said that we will try to reach to around 14% to 15%, after that we said we will be reaching to around 13%. But I think now we are just understanding that we will be reaching something 11% to 12%."
Growth Drivers & Pipeline
- Paracetamol is the named FY27 growth driver: Capacity is being expanded gradually, and the molecule is central to next year's revenue plan. The current plant is underutilized at ~60%, so volume upside exists without new assets.
- Non-ibuprofen conversion to regulated markets: Management plans to shift domestic non-ibuprofen API sales into regulated markets, which would improve realizations and margin quality.
- Metformin capacity being reactivated: A facility previously used for paracetamol will be converted back to metformin or other products, adding capacity without fresh capex.
- Minoxidil API commercialization: A CEP has been received; the intermediate is already sold on a merchant basis. Final API for international regulated markets is expected to start by Q1 FY27.
- Forward integration via CMO, not formulations: The company plans a contract manufacturing model for APIs rather than entering finished formulations.
- R&D pipeline is generic, details withheld: Management confirmed work on generic molecules but declined to name products or timelines, saying announcements will come when ready.
- New land parcel progressing: Environmental clearance is granted; approvals from highway authorities and consents to operate are next. Products are still being finalized but will span both API and chemicals.
Capital Allocation & Competitive Positioning
- FY27 capex steady at INR150–200 crores: Split roughly 60% growth and 40% infrastructure/automation. Management did not break out the pharma-vs-chemicals allocation or specify incremental capacity.
- Not chasing distressed competitor assets: Asked about Solara's ibuprofen plant, management said it is not immediately interested; priority is developing its own new land. It would consider an acquisition only if the opportunity fits selection parameters.
- Geographic focus remains Europe and MENA: The company will also look at other regions, with the export push covering both API and chemical segments.
- Three process patents, none commercial: Patents cover sitagliptin, vildagliptin, and losartan, but nitrosamine impurity issues and enzyme-usage problems have kept them from commercial scale.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q4 EBITDA margin improvement | Increase by 1–2% from Q3 levels; recover INR2–3 crores miss | Q4 FY26 |
| FY27 revenue growth | Minimum 10–15% top-line growth | FY27 |
| FY27 bottom-line growth | 15–20% growth | FY27 |
| FY27 capex | INR150–200 crores, 60:40 growth vs infra/automation split | FY27 |
| Revenue mix | 60% API, 40% chemical | Within 2 years |
| API sub-mix | 50% ibuprofen, 50% non-ibuprofen | Near-term (undated) |
| Minoxidil API commercialization | Final API for regulated international markets | Q1 FY27 |
| FY27 revenue target | INR2,700 crores (INR1,800 cr API, INR900 cr chemical) | FY27 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue from operations | ₹580 cr, +10.9% YoY |
| EBITDA | ₹62.6 cr, +22.8% YoY |
| EBITDA margin | 10.7%, up from 9.7% YoY |
| PBT before exceptional items | ₹38.8 cr, +39.3% YoY |
| PBT margin | 6.6%, up from 5.3% YoY |
| Exceptional item | ₹11.2 cr, provision for new labour law, non-recurring |
| 9M FY26 revenue | ₹1,699.6 cr, +9.6% YoY |
| 9M FY26 EBITDA margin | 11.4%, up from 10% YoY |
| Pharma segment revenue | ₹356 cr, 61% of total revenue |
| Chemical segment revenue | ₹224 cr, 39% of total revenue |
| Ibuprofen API revenue | ₹228 cr, 64% of pharma revenue |
| Non-ibuprofen API revenue | ₹128 cr, 36% of pharma revenue, up from 34% YoY |
| Ibuprofen capacity utilisation | 90–95% |
| Chemicals capacity utilisation | near 200% |
| Paracetamol capacity utilisation | ~60%, expansion underway |
| FY27 revenue target | ₹2,700 cr, with ₹1,800 cr from API and ₹900 cr from chemicals |
| FY27 top-line growth guidance | 10–15% minimum |
| FY27 bottom-line growth guidance | 15–20% |
| Q4 FY26 revenue expectation | ₹600 cr |
| Q4 FY26 EBITDA margin expectation | ~11%, slightly better than Q3 |
| FY26 capex | ₹130–135 cr, 60% growth, 40% infra and automation |
| Total inventory | ~₹350 cr |